PressAugust 15, 2023 Filament Health and Nasdq-Listed SPAC Jupiter Acquisition Corp. Announce Filing of SEC Registration Statement
PressAugust 14, 2023 Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
PressAugust 14, 2023 NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
PressAugust 11, 2023 Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer
PressAugust 11, 2023 atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
PressAugust 11, 2023 Enthea Reports Clinical Results from First Year of Psychedelic Healthcare Benefit for Employees of Leading California-Based Soap Company
PressAugust 10, 2023 Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023
PressAugust 10, 2023 atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
PressAugust 8, 2023 Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
PressAugust 8, 2023 Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
PressAugust 8, 2023 Filament Health Announces FDA Approval of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010
PressAugust 8, 2023 Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
PressAugust 4, 2023 Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
PressAugust 4, 2023 MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
PressAugust 4, 2023 FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink